Publications by authors named "M de Bast"

Article Synopsis
  • Mantle cell lymphoma (MCL) varies in prognosis, with blastoid and pleomorphic variants generally having poorer outcomes.
  • A study involving 1029 MCL patients over 15 years focused on the characteristics and survival rates of those with these variants, finding a median progression-free survival (PFS) of 38 months and overall survival (OS) of 68 months.
  • Key factors influencing PFS included receiving autologous hematopoietic transplantation (auto-HCT) and MCL International Prognostic Index (MIPI) scores; however, auto-HCT did not improve OS, indicating its benefits are more related to managing the disease's progression rather than overall survival.
View Article and Find Full Text PDF

The reduced transition probabilities for the 4_{1}^{+}→2_{1}^{+} and 2_{1}^{+}→0_{1}^{+} transitions in ^{92}Mo and ^{94}Ru and for the 4_{1}^{+}→2_{1}^{+} and 6_{1}^{+}→4_{1}^{+} transitions in ^{90}Zr have been determined in this experiment making use of a multinucleon transfer reaction. These results have been interpreted on the basis of realistic shell-model calculations in the f_{5/2}, p_{3/2}, p_{1/2}, and g_{9/2} proton valence space. Only the combination of extensive lifetime information and large scale shell-model calculations allowed the extent of the seniority conservation in the N=50 g_{9/2} orbital to be understood.

View Article and Find Full Text PDF

Unidirectional double-hydrogen (2H) and triple-hydrogen (3H) rearrangement reactions occur upon electron-ionization-induced fragmentation of -2-(4-,-dimethylaminobenzyl)-1-indanol (), -2-(4-methoxybenzyl)-1-indanol (), 4-(4-,-dimethylaminophenyl)-2-butanol (), and related compounds, as reported some 35 years ago (Kuck, D.; Filges, U. , , 643-653).

View Article and Find Full Text PDF

Purpose: Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger.

View Article and Find Full Text PDF